ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. ICT-107 is designed to activate a patient’s immune system to target six different tumor-associated antigens.


In June 2017, unable to secure sufficient additional financial resources to complete the phase 3 registration trial of ICT-107, ImmunoCellular wound down the trial.



Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved